查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933352

全球肺炎鏈球菌疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量、未來預測（2026-2034）

Pneumococcal Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 請詢問到貨日

價格

肺炎鏈球菌疫苗市場成長驅動因子

全球肺炎鏈球菌疫苗市場正經歷穩定成長，這主要得益於疫苗接種意識的提高、肺炎球菌感染率的上升以及疫苗技術的不斷進步。根據 Fortune Business Insights 的數據顯示，2025 年全球肺炎鏈球菌疫苗市場規模為 88 億美元。預計該市場將從 2026 年的 91.5 億美元成長到 2034 年的 147.6 億美元，預測期內複合年增長率 (CAGR) 為 6.17%。北美地區憑藉著強大的疫苗接種計劃和主要疫苗生產商的存在，在 2025 年佔了 29.20% 的市場佔有率，成為市場主導者。

肺炎鏈球菌疫苗用於預防由肺炎鏈球菌引起的感染，該菌可導致肺炎、腦膜炎和敗血症等嚴重疾病。葛蘭素史克 (GSK plc)、默克公司 (Merck & Co., Inc.) 和賽諾菲 (Sanofi) 等知名公司持續投資研發新產品，以滿足日益增長的對更廣泛血清型覆蓋的需求。此外，有利的政府政策和加速的監管審批也促進了市場成長。

市場動態

市場驅動因素

侵襲性肺炎鏈球菌疾病 (IPD) 的日益增加是市場成長的主要驅動因素。與慢性疾病、HIV 感染、人口老化和社會健康決定因素相關的病例數量不斷增加，進一步提高了疫苗接種的需求。根據歐洲疾病預防控制中心 (ECDC) 的報告，歐盟/歐洲經濟區 (EU/EEA) 地區 2022 年確診的侵襲性肺炎球菌病 (IPD) 病例數預計將達到 17,700 例，凸顯了該疾病負擔的日益加重。醫療保健支出增加，且更重視預防而非治療，也進一步推動了市場擴張。

市場限制因子

肺炎鏈球菌疫苗的生產過程仍然十分複雜，構成了一項主要限制因素。此生產流程需要針對多種肺炎鏈球菌血清型，並將多醣體與蛋白質載體結合，這需要專門的設施、先進的設備和高水準的技術專長。這些因素增加了生產成本，並限制了生產規模的擴大，尤其對於新興生產商而言。

市場機會

對下一代候選疫苗研發管線的投資增加帶來了巨大的成長機會。現有的結合疫苗並未涵蓋所有致病血清型，這為創新留下了空間。各公司正在研發高滴度蛋白疫苗，以提供更廣泛的保護。賽諾菲將於2024年12月啟動PCV21的III期臨床試驗，並擴大與SK Biosciences的合作，顯示先進疫苗具有巨大的成長潛力。

市場挑戰

缺乏足夠的冷藏基礎設施構成了一項重大挑戰，尤其是在中低收入國家。肺炎鏈球菌疫苗需要在2°C至8°C的溫度下儲存，冷鏈物流中斷會導致疫苗降解並降低效力。報告顯示，全球25%的液體疫苗因冷鏈故障而降解，阻礙了疫苗的有效分發。

肺炎鏈球菌疫苗市場趨勢

一個值得注意的市場趨勢是，人們越來越重視成人疫苗接種計畫。肺炎鏈球菌疾病在65歲及以上成年人中導致較高的死亡率。政府主導的措施和更新的疫苗接種指南正在擴大成人疫苗接種覆蓋率。 2024年10月，美國疾病管制與預防中心 (CDC) 將肺炎鏈球菌結合疫苗 (PCV) 的建議接種年齡範圍擴大到所有50歲及以上的未接種疫苗的成年人，進一步推動了市場成長。

依細分市場分析

依產品類型劃分，市場分為PCV13、PCV15、PCV20、PCV21、PPSV23和其他疫苗。 PCV20市佔率領先，這得益於其更廣泛的血清型覆蓋範圍和更多的核准產品。 PPSV23市佔率預計將穩定成長，這主要歸功於其在聯合免疫接種計劃中的廣泛應用。

依年齡組劃分，兒科市場佔主導地位，這主要得益於兒童對疾病的高易感性和廣泛的兒童疫苗接種計劃。由於教育活動和財政支持計劃，成人​​市場預計將保持穩定的複合年增長率。

依分銷管道劃分，由於大規模公共疫苗接種計劃以及與國際組織的合作，政府供應商佔市場主導地位。由於疫苗取得管道的改善，醫院和零售藥局也實現了強勁成長。

區域展望

北美地區憑藉先進的醫療基礎設施和持續的研發投入，預計將保持領先地位，2025年市場規模為48.3億美元，2026年為48.7億美元。

歐洲市場佔第二大佔有率，這得益於快速的監管審批和積極的研究活動。

亞太地區預計將實現最快成長，這主要得益於疫苗接種計劃的擴展以及價格合理的國產疫苗的開發。

拉丁美洲以及中東和非洲地區預計將實現溫和成長，這主要得益於疫苗接種活動的增加和區域合作。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵洞察

  • 主要國家和地區的監管環境
  • 主要國家和地區的疫苗接種率
  • 主要國家和地區的肺炎球菌疫苗政府免疫計劃
  • 小兒麻痺疫苗市場的技術進步
  • 主要產業趨勢（併購、合作、新產品發表）等等）

第五章：全球肺炎鏈球菌疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品類型劃分
    • PCV13
    • PCV15
    • PCV20
    • PCV21
    • PPSV23
    • 其他
  • 市場分析、洞察與預測：依年齡組別劃分
    • 兒童
    • 成人
  • 市場分析、洞察與預測：依銷售管道劃分
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美肺炎鏈球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲肺炎鏈球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章 亞太地區肺炎鏈球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲肺炎鏈球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲肺炎鏈球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析 (2025)
  • 公司簡介
    • GSK plc.
    • Merck &Co., Inc.
    • Abbott
    • Sanofi
    • Pfizer
    • Inventprise
    • Vaxcyte
    • Walvax Biotechnology Co., Ltd.
    • SK Bioscience
Product Code: FBI113672

Growth Factors of pneumococcal vaccines Market

The global pneumococcal vaccines market is witnessing consistent growth, supported by increasing awareness of vaccination, rising prevalence of pneumococcal diseases, and continuous advancements in vaccine technology. According to Fortune Business Insights, the global pneumococcal vaccines market was valued at USD 8.8 billion in 2025. The market is projected to grow from USD 9.15 billion in 2026 to USD 14.76 billion by 2034, registering a CAGR of 6.17% during the forecast period. North America dominated the market with a share of 29.20% in 2025, driven by strong immunization programs and the presence of leading vaccine manufacturers.

Pneumococcal vaccines are administered to prevent infections caused by Streptococcus pneumoniae, which can lead to severe diseases such as pneumonia, meningitis, and sepsis. Established players including GSK plc., Merck & Co., Inc., and Sanofi continue to invest in pipeline development to address the rising demand for broader serotype coverage. Additionally, favorable government policies and accelerated regulatory approvals are strengthening market growth.

Market Dynamics

Market Drivers

The increasing prevalence of invasive pneumococcal diseases (IPD) is a key driver of market growth. Rising cases associated with chronic illnesses, HIV infections, aging populations, and social determinants of health have intensified the need for preventive vaccination. The European Centre for Disease Prevention and Control reported 17,700 confirmed IPD cases in the EU/EEA in 2022, highlighting the growing disease burden. Increased healthcare expenditure focused on prevention rather than treatment further supports market expansion.

Market Restraints

The complexity of pneumococcal vaccine manufacturing remains a significant restraint. The production process involves targeting multiple pneumococcal serotypes and conjugating polysaccharides to protein carriers, which requires specialized facilities, advanced equipment, and high technical expertise. These factors increase manufacturing costs and limit scalability, particularly for emerging manufacturers.

Market Opportunities

Rising investment in next-generation pipeline candidates presents substantial growth opportunities. Existing conjugate vaccines do not cover all disease-causing serotypes, leaving room for innovation. Companies are developing higher-valent and protein-based vaccines to provide broader protection. In December 2024, Sanofi initiated a Phase 3 program for PCV21 and expanded collaboration with SK Bioscience, underlining strong growth potential for advanced vaccines.

Market Challenges

The lack of adequate cold storage infrastructure poses a major challenge, especially in low- and middle-income countries. Pneumococcal vaccines require storage between 2°C and 8°C, and disruptions in cold chain logistics can lead to vaccine spoilage and reduced efficacy. Reports indicate that 25% of liquid vaccines are spoiled globally due to cold chain failures, hampering effective distribution.

Pneumococcal Vaccines Market Trends

A notable trend in the market is the increasing focus on adult vaccination programs. Pneumococcal diseases cause high mortality among adults aged 65 years and older. Government initiatives and updated vaccination guidelines are expanding adult immunization coverage. In October 2024, the U.S. CDC expanded age-based PCV recommendations to include all PCV-naive adults aged 50 years and above, supporting market growth.

Segmentation Analysis

By product type, the market is segmented into PCV13, PCV15, PCV20, PCV21, PPSV23, and others. The PCV20 segment holds a leading share, driven by broader serotype coverage and increasing approvals. The PPSV23 segment is expected to grow steadily due to its widespread use in combination immunization schedules.

By age group, the pediatric segment dominates the market, supported by high disease susceptibility in children and extensive childhood immunization programs. The adult segment is expected to grow at a stable CAGR, driven by awareness initiatives and financial support programs.

By distribution channel, government suppliers dominate the market, owing to large-scale public immunization programs and collaborations with global organizations. Hospital and retail pharmacies are also witnessing strong growth due to improved accessibility.

Regional Outlook

North America led the market with a valuation of USD 4.83 billion in 2025 and USD 4.87 billion in 2026, supported by advanced healthcare infrastructure and continuous R&D investments.

Europe holds the second-largest share, driven by fast-track regulatory approvals and strong research activity.

Asia Pacific is projected to register the fastest growth, supported by expanding immunization programs and development of affordable indigenous vaccines.

Latin America and the Middle East & Africa are expected to grow moderately due to increasing vaccination drives and regional collaborations.

Competitive Landscape

The global pneumococcal vaccines market is semi-consolidated, with key players such as Sanofi, Merck & Co., Inc., GSK plc., Pfizer, and Abbott holding significant market shares. These companies focus on strategic expansions, regulatory approvals, and pipeline advancements. Emerging players including Vaxcyte, Inventprise, and Walvax Biotechnology are also strengthening their presence through clinical development and partnerships.

Conclusion

The global pneumococcal vaccines market is positioned for steady growth over the forecast period, supported by rising disease prevalence, expanding immunization programs, and continuous innovation in higher-valent vaccine development. With the market valued at USD 8.8 billion in 2025, projected to reach USD 9.15 billion in 2026 and USD 14.76 billion by 2034, strong government support, pipeline expansion, and growing focus on both pediatric and adult vaccination are expected to drive long-term market expansion despite challenges related to manufacturing complexity and cold chain infrastructure.

Segmentation

By Product Type

  • PCV13
  • PCV15
  • PCV20
  • PCV21
  • PPSV23
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Product Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product Type, Age Group, Distribution Channel, and Country)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Pneumococcal Vaccines- By Key Countries/ Regions
  • 4.4. Technological Advancements in Polio Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. PCV13
    • 5.1.2. PCV15
    • 5.1.3. PCV20
    • 5.1.4. PCV21
    • 5.1.5. PPSV23
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Pediatric
    • 5.2.2. Adults
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. PCV13
    • 6.1.2. PCV15
    • 6.1.3. PCV20
    • 6.1.4. PCV21
    • 6.1.5. PPSV23
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Pediatric
    • 6.2.2. Adults
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. PCV13
    • 7.1.2. PCV15
    • 7.1.3. PCV20
    • 7.1.4. PCV21
    • 7.1.5. PPSV23
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Pediatric
    • 7.2.2. Adults
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. PCV13
    • 8.1.2. PCV15
    • 8.1.3. PCV20
    • 8.1.4. PCV21
    • 8.1.5. PPSV23
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Pediatric
    • 8.2.2. Adults
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. PCV13
    • 9.1.2. PCV15
    • 9.1.3. PCV20
    • 9.1.4. PCV21
    • 9.1.5. PPSV23
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Pediatric
    • 9.2.2. Adults
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. PCV13
    • 10.1.2. PCV15
    • 10.1.3. PCV20
    • 10.1.4. PCV21
    • 10.1.5. PPSV23
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Age Group
    • 10.2.1. Pediatric
    • 10.2.2. Adults
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital & Retail Pharmacies
    • 10.3.2. Government Suppliers
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products Types
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck & Co., Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products Types
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Abbott
      • 11.2.3.1. Overview
      • 11.2.3.2. Products Types
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products Types
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer
      • 11.2.5.1. Overview
      • 11.2.5.2. Products Types
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Inventprise
      • 11.2.6.1. Overview
      • 11.2.6.2. Products Types
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Vaxcyte
      • 11.2.7.1. Overview
      • 11.2.7.2. Products Types
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Walvax Biotechnology Co., Ltd.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products Types
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. SK Bioscience
      • 11.2.9.1. Overview
      • 11.2.9.2. Products Types
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 3: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 6: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 7: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 9: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 10: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 11: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 13: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 14: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 15: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 17: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 18: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 19: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 21: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 22: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 23: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Pneumococcal Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 4: Global Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Pneumococcal Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 7: North America Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 8: North America Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 9: North America Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 10: North America Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Pneumococcal Vaccines Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Pneumococcal Vaccines Market Value Share (%), by Country, 2025
  • Figure 14: Europe Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 15: Europe Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 16: Europe Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 17: Europe Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 18: Europe Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 21: Europe Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 22: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 23: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 24: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 25: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 26: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 29: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 30: Latin America Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 31: Latin America Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 32: Latin America Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 33: Latin America Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 34: Latin America Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 37: Latin America Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 38: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 39: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
  • Figure 40: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 41: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 42: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 45: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 46: Global Pneumococcal Vaccines Market Share (%), by Company, 2025